CLASS OF PLATINUM COMPOUNDS FOR TREATING CANCER, AND METHOD FOR PREPARATION THEREOF
20230339997 · 2023-10-26
Inventors
Cpc classification
C07K5/0827
CHEMISTRY; METALLURGY
A61K47/6425
HUMAN NECESSITIES
A61K47/643
HUMAN NECESSITIES
A61K47/6851
HUMAN NECESSITIES
A61P35/00
HUMAN NECESSITIES
International classification
C07F15/00
CHEMISTRY; METALLURGY
A61K47/64
HUMAN NECESSITIES
A61K47/68
HUMAN NECESSITIES
A61P35/00
HUMAN NECESSITIES
Abstract
Provided is the novel class of platinum compounds shown in formula (I), and their use as pharmaceutical agents, especially for treating cancer alone or in combination and for preventing cancer. The described novel platinum compounds have been shown, through experimentation, to have superior in vivo antitumor effects, significantly better than the clinical drug carboplatin, and to have significantly improved the aqueous solubility of platinum-based drugs, and can be made into lyophilized powder or injectable solution, resolving the defect of inconvenient clinical use. In view of the foregoing, the disclosed class of platinum compounds has good prospects for clinical application.
##STR00001##
Claims
1. A compound represented by the following formula (I) or a pharmaceutically acceptable salt thereof, ##STR00352## wherein: R.sub.1 and R.sub.2 are linked together to form the following structure: ##STR00353## R.sub.3 is a group with certain functionalities, wherein R.sub.3 is able to effectively enhance the targeting or water solubility of platinum compounds.
2. The compound represented by formula (I) or the pharmaceutically acceptable salt thereof as claimed in claim 1, wherein, R.sub.1 and R.sub.2 are linked together to form moiety (A1), (A2), (A3) or (A4): ##STR00354##
3. The compound represented by formula (I) or the pharmaceutically acceptable salt thereof as claimed in claim 1, wherein, R.sub.1 and R.sub.2 are linked together to form moiety (A1), (A2), (A3) or (A4), and the general formula of this series of platinum compounds is: ##STR00355##
4-6. (canceled)
7. The compound represented by formula (I) or the pharmaceutically acceptable salt thereof as claimed in claim 1, R.sub.3 is a group with certain functionalities, wherein R.sub.3 is able to effectively enhance the targeting or water solubility of platinum compounds; R.sub.3 is the following structure: ##STR00356## wherein, X is C or O; R.sub.4 is a linker, which has the function of improving the water solubility of the compound; R.sub.5 is a group with targeting function.
8. The compound represented by formula (I) or the pharmaceutically acceptable salt thereof as claimed in claim 1, wherein, R.sub.4 is selected from: C.sub.1-12 alkyl, C.sub.1-12 alkoxy, C.sub.1-12 alkylcarbonyl, phenoxy or phenylamino optionally substituted by 1 to 2 halogens, C.sub.1-12 alkylamino, C.sub.1-12 alkoxy-C.sub.1-12 alkylamino, C.sub.1-12 alkylcarbonyloxy, C.sub.1-12 alkyl-C.sub.3-8 cycloalkylcarbonyloxy, (C.sub.1-4 alkyl-O).sub.m—C.sub.1-12 alkylcarbonyloxy, C.sub.1-12 alkylcarbonylamino-(C.sub.1-4 alkyl-O).sub.m—C.sub.1-12 alkylcarbonyloxy, C.sub.1-12 alkylcarbonylamino and phenyl-C.sub.1-12 alkylcarbonylamino.
9. The compound represented by formula (I) or the pharmaceutically acceptable salt thereof as claimed in claim 1, wherein, R.sub.4 is the following structure: ##STR00357## ##STR00358##
10. The compound represented by formula (I) or the pharmaceutically acceptable salt thereof as claimed in claim 1, wherein, R.sub.5 is: human serum albumin HAS; an antibody that binds to a tumor-associated antigen; or, a molecule that is able to specifically bind to a tumor cell surface integrin receptor.
11. The compound represented by formula (I) or the pharmaceutically acceptable salt thereof as claimed in claim 1, wherein, R.sub.5 is the molecule that is able to specifically bind to the tumor cell surface integrin receptor.
12. The compound represented by formula (I) or the pharmaceutically acceptable salt thereof as claimed in claim 1, wherein, R.sub.5 is the molecule that is able to specifically bind to an integrin, and comprises an arginine-glycine-aspartic acid (RGD) tripeptide sequence in chemical structure.
13. The compound represented by formula (I) or the pharmaceutically acceptable salt thereof as claimed in claim 1, wherein, the general structure formula is shown in any one of the following structures: ##STR00359## ##STR00360##
14. The compound represented by formula (I) or the pharmaceutically acceptable salt thereof as claimed in claim 1, wherein, the compound represented by formula (I) is: ##STR00361## ##STR00362## ##STR00363## ##STR00364## ##STR00365## ##STR00366## ##STR00367## ##STR00368## ##STR00369## ##STR00370## ##STR00371## ##STR00372## ##STR00373## ##STR00374## ##STR00375## ##STR00376## ##STR00377##
15. A pharmaceutical composition, comprising the compound represented by formula (I) or the pharmaceutically acceptable salt thereof as claimed in claim 1 and a pharmaceutically acceptable carrier.
16-17. (canceled)
18. A method for preventing and/or treating cancer, comprising administering a therapeutically effective amount of the compound represented by formula (I) or the pharmaceutically acceptable salt thereof as claimed in claim 1 to a patient, wherein, the compound represented by the formula (I) or the pharmaceutically acceptable salt is administered in combination with an anticancer medicament and/or in combination with radiotherapy and/or immunotherapy.
19. A method for preventing and/or treating cancer, comprising administering a therapeutically effective amount of the compound represented by formula (I) or the pharmaceutically acceptable salt thereof as claimed in claim 1 to a patient.
20. The compound represented by formula (I) or the pharmaceutically acceptable salt thereof as claimed in claim 10, wherein, the antibody is an anti-folate receptor α antibody, an anti-mesothelin antibody, an anti-Her2 antibody, an anti-EGFR antibody, an anti-VEGFR antibody, an anti-CD20 antibody, an anti-CD22 antibody, an anti-CD28 antibody, an anti-CD33 antibody or an anti-BR96 antibody.
21. The compound represented by formula (I) or the pharmaceutically acceptable salt thereof as claimed in claim 11, wherein, the integrin receptor is αvβ3, αvβ6 or α5β1.
22. The compound represented by formula (I) or the pharmaceutically acceptable salt thereof as claimed in claim 12, wherein, R.sub.5 is ##STR00378## ##STR00379## ##STR00380##
23. The method as claimed in claim 19, wherein, the cancer is gastrointestinal cancer, colorectal cancer, colon cancer, liver cancer, hepatocellular carcinoma, pancreatic cancer, biliary tract cancer, gastric cancer, urogenital system cancer, bladder cancer, testicular cancer, cervical cancer, malignant mesothelioma, osteogenic sarcoma, esophageal cancer, laryngeal cancer, prostate cancer, hormone-resistant prostate cancer, lung cancer, small cell lung cancer, non-small cell lung cancer, breast cancer, triple negative breast cancer, breast cancer with BRCA1 and/or BRCA2 gene mutations, blood cancer, leukemia, acute primitive lymphoblastic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, chronic myeloid leukemia, lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, follicular lymphoma, diffuse large B-cell lymphoma, ovarian cancer, brain cancer, neuroblastoma, Ewing sarcoma, renal cell carcinoma, epidermoid carcinoma, skin cancer, melanoma, head and/or neck cancer, head and neck squamous cell carcinoma or oral cancer.
24. The method as claimed in claim 23, wherein, the cancer is colorectal cancer, colon cancer, pancreatic cancer, lung cancer, non-small cell lung cancer, ovarian cancer, cervical cancer, melanoma, head and/or neck cancer, or head and neck squamous cell carcinoma.
Description
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0035] Embodiments of the present disclosure will be described in detail below in combination with examples, but those skilled in the art will understand that the following examples are only for illustrating the present disclosure, and should not be regarded as limiting the scope of the present disclosure. If no specific conditions are specified in the example, the experimental methods usually follow the conventional conditions or the conditions recommended by the manufacturer. If the manufacturer is not indicated in the reagents or instruments used, they are all conventional products that can be obtained from the market.
[0036] The structures of the compounds were determined by liquid chromatography-mass spectrometry (HPLC-MS). The mass spectrum was determined by watersZQ2000 mass spectrometer, manufacturer: Waters, model: ZQ2000.
[0037] When liquid chromatography-mass spectrometry was used for determination, the model of liquid chromatography instrument was Water 2695HPLC Waters 2998, detector: ultraviolet detector, chromatographic column: YMC pack ODS-AQ 100*4.6 mm*5 μm. The detection conditions of the liquid chromatograph were as follows: [0038] chromatographic column temperature: 35° C.; flow rate: 1 mL/min; detection wavelength: 214 nm; gradient elution: (0 min: 90% (v/v) A, 10% (v/v) B; 10 min: 10% (v/v)A, 90% (v/v)B; 15 min: 10% (v/v)A, 90% (v/v)B; 15.1 min: 90% (v/v)A, 10% (v/v)B; 20 min: 90% (v/v)A, 10% (v/v)B); mobile phase A: 0.1% formic acid; mobile phase B: acetonitrile.
[0039] When the liquid phase instrument was used for purification, the instrument used was Dalian Elite preparative liquid chromatograph, model: P270, detector: ultraviolet detector, chromatographic column: C18 reversed-phase silica gel 20*250 mm. The preparation method of the preparative high performance liquid chromatograph was as follows: [0040] chromatographic column temperature: 25° C.; detection wavelength: 214 nm; elution gradient: (0 min: 85% (v/v)A, 15% (v/v)B, flow rate: 25 mL/min; 8 min: 20% (v/v)A, 80% (v/v)B, flow rate: 25 mL/min; 8.01 min: 5% (v/v)A, 95% (v/v)B, flow rate: 40 mL/min; 10 min: 5% (v/v)A, 95% (v/v)B, flow rate: 40 mL/min; 10.01 min: 50% (v/v)A, 50% (v/v)B, flow rate: 40 mL/min; 12 min: 50% (v/v)A, 50% (v/v)B, flow rate: 40 mL/min); mobile phase A: 0.01% formic acid/H.sub.2O; mobile phase B: acetonitrile.
[0041] Thin layer chromatography (TLC) was used for reaction detection. The development system used was dichloromethane:methanol=10:1 (volume ratio).
[0042] The digital display magnetic stirrer was used as the stirrer. Manufacturer: Dragon Laboratory Instruments, model: MS-H280-Pro.
[0043] The general synthesis method of the examples was as follows:
##STR00042## [0044] A1-A4 and
##STR00043## were subjected to a coupling reaction to produce
##STR00044## (i.e., examples 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 22, 23, 24, 25, 27, 29, 30, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63); [0045] A1-A4 and
##STR00045## were subjected to a coupling reaction to produce
##STR00046## (i.e., examples 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 26, 28, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64);
##STR00047## [0046] and R.sub.5 were subjected to an addition reaction to produce
##STR00048## (i.e., examples 65, 67, 69, 70, 71, 72, 77, 78, 79, 80, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95);
##STR00049## [0047] and R.sub.5 were subjected to an addition reaction to produce
##STR00050## (i.e., examples 66, 68, 73, 74, 75, 76, 81, 82, 83, 84, 96, 97).
[0048] Taking example S1 and example 65 as examples, the specific implementation process was as follows:
##STR00051##
[0049] 1) In a 50 mL single-necked flask, A1 (177.2 mg, 0.46 mmol), 2-(aminooxy)-N-(2-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)ethyl)acetamide (98 mg 0.46 mmol) were weighed in turn, and after dissolving by adding 15 mL of N,N-dimethylformamide, 4 A molecular sieve (162 mg) was added, and the reaction system was replaced with nitrogen. The reaction solution was reacted overnight at room temperature. The reaction solution was evaporated to dryness by rotary evaporation under reduced pressure, and the crude product was purified by silica gel column chromatography to obtain a white solid (169.0 mg, yield of 63.3%), i.e., example S1.
##STR00052##
[0050] 2) In a 50 mL single-necked flask, example S1 (151 mg, 0.26 mmol) and R5-1 (117.5 mg, 0.26 mmol) were weighed in turn, then 15 mL of methanol was added, and the reaction system was replaced with nitrogen, and the reaction solution was reacted overnight at room temperature. The reaction solution was evaporated to dryness by rotary evaporation under reduced pressure, and refined and separated by semi-preparative HPLC, and freeze-dried by a freeze dryer to obtain a white solid (181.2 mg, yield of 65%), i.e., example S65.
[0051] A. When R.sub.4 and R.sub.5 were respectively different substituents, the compounds shown in Table 1 below could be obtained, i.e., examples S1-S97.
TABLE-US-00001 TABLE 1 Structures of Examples Substituent Example R.sub.3:
[0052] The detection results of mass spectrometry (MS) confirmed that the molecular weights of compounds S1-S97 are sequentially shown in the following Table 2, which are consistent with the molecular weights predicted by structural calculation:
TABLE-US-00002 TABLE 2 Mass spectrometry detection results of examples Mass Predicted spectrometry molecular Number detection weight Property Yield S1 581 580.42 white solid 195.2 mg S2 579 578.45 white solid 185.3 mg S3 699 697.61 white solid 164.8 mg S4 697 695.64 white solid 221.1 mg S5 693 691.58 white solid 236.2 mg S6 691 689.61 white solid 160.5 mg S7 635 634.48 white solid 175.3 mg S8 634 632.51 white solid 198.7 mg S9 629 627.48 white solid 178.2 mg S10 627 625.51 white solid 154.1 mg S11 623 621.51 white solid 198.0 mg S12 621 619.54 white solid 162.8 mg S13 639 637.58 white solid 140.4 mg S14 637 635.60 white solid 187.3 mg S15 567 566.39 white solid 194.2 mg S16 565 564.42 white solid 146.7 mg S17 593 592.47 white solid 137.2 mg S18 592 590.50 white solid 172.3 mg S19 640 638.50 white solid 154.3 mg S20 638 636.53 white solid 169.5 mg S21 593 592.47 white solid 148.4 mg S22 711 709.58 white solid 128.3 mg S23 593 592.47 white solid 136.2 mg S24 713 711.60 white solid 154.0 mg S25 620 618.51 white solid 167.3 mg S26 618 616.54 white solid 174.2 mg S27 591 590.46 white solid 129.4 mg S28 589 588.48 white solid 137.3 mg S29 701 699.54 white solid 168.4 mg S30 785 783.70 white solid 174.2 mg S31 662 660.55 white solid 146.5 mg S32 660 658.58 white solid 150.8 mg S33 662 660.55 white solid 114.7 mg S34 660 658.58 white solid 154.2 mg S35 708 706.57 white solid 163.9 mg S36 706 704.60 white solid 118.5 mg S37 716 714.61 white solid 132.6 mg S38 716 714.60 white solid 147.6 mg S39 714 712.64 white solid 170.2 mg S40 760 758.67 white solid 182.4 mg S41 709 707.61 white solid 106.3 mg S42 707 705.64 white solid 114.7 mg S43 709 707.61 white solid 119.1 mg S44 707 705.64 white solid 150.6 mg S45 755 753.63 white solid 164.2 mg S46 753 751.66 white solid 108.2 mg S47 791 789.71 white solid 115.6 mg S48 789 787.73 white solid 120.3 mg S49 791 789.71 white solid 184.2 mg S50 790 787.73 white solid 175.6 mg S51 837 835.73 white solid 114.3 mg S52 835 833.76 white solid 120.4 mg S53 700 698.64 white solid 126.5 mg S54 698 696.67 white solid 156.3 mg S55 700 698.64 white solid 165.8 mg S56 698 696.67 white solid 117.3 mg S57 746 744.67 white solid 120.6 mg S58 744 742.69 white solid 124.0 mg S59 672 670.59 white solid 148.6 mg S60 670 668.61 white solid 152.3 mg S61 672 670.59 white solid 119.3 mg S62 670 668.61 white solid 114.6 mg S63 718 716.61 white solid 132.6 mg S64 716 714.64 white solid 124.1 mg S65 1073 1071.94 white solid 118.3 mg S66 1071 1069.97 white solid 128.6 mg S67 1029 1027.93 white solid 147.3 mg S68 1027 1025.96 white solid 136.2 mg S69 1085 1083.99 white solid 127.6 mg S70 1041 1039.98 white solid 135.6 mg S71 1301 1300.28 white solid 128.4 mg S72 2495 2493.64 white solid 140.2 mg S73 1083 1082.02 white solid 117.4 mg S74 1039 1038.01 white solid 121.0 mg S75 1299 1298.30 white solid 123.6 mg S76 2493 2491.67 white solid 130.5 mg S77 1131 1130.02 white solid 140.0 mg S78 1087 1086.01 white solid 134.2 mg S79 1347 1346.30 white solid 198.9 mg S80 2541 2539.67 white solid 186.4 mg S81 1129 1128.05 white solid 102.3 mg S82 1085 1084.04 white solid 89.6 mg S83 1345 1344.33 white solid 78.5 mg S84 2539 2537.69 white solid 94.3 mg S85 1148 1147.05 white solid 84.6 mg S86 1408 1407.05 white solid 91.7 mg S87 2602 2600.71 white solid 74.9 mg S88 1200 1199.13 white solid 69.8 mg S89 1156 1155.12 white solid 79.4 mg S90 1200 1199.13 white solid 88.4 mg S91 1156 1155.12 white solid 76.9 mg S92 1246 1245.15 white solid 124.1 mg S93 1202 1201.14 white solid 108.4 mg S94 1407 1406.44 white solid 154.6 mg S95 2601 2599.81 white solid 134.2 mg S96 1405 1404.47 white solid 112.7 mg S97 2599 2597.84 white solid 143.7 mg
[0053] In Vitro Water Solubility Experiment of Example
[0054] In order to compare the difference in water solubility between the platinum compounds of the present disclosure and the marketed drugs cisplatin, carboplatin and oxaliplatin, the water solubility at room temperature was determined. At room temperature of 25° C., the test sample that had been ground into a fine powder was weighed accurately, and shaken vigorously for 30 seconds every 5 minutes in a certain volume of distilled water; and the dissolution of each test sample was observed within 30 minutes. If no visible solute particles were visible, the sample was considered to be completely dissolved. The experimental results of the solubility of the test sample in water are shown in Table 3.
TABLE-US-00003 TABLE 3 Solubility of the test sample in water Plati- Solu- num bility com- (mg/ pound Structure mL) Cis- platin
[0055] Conclusions: The water solubility of marketed drugs cisplatin and oxaliplatin is poor, both of which are less than 6 mg/mL. The solubility of carboplatin is slightly better, reaching 16.6 mg/mL in water. However, the water solubility of the examples S47, S72, S80, S95 and S97S disclosed by the present disclosure are significantly improved compared with the marketed drugs. Especially the water solubility of example 72 and example S80, compared with carboplatin, the water solubility has nearly a 1-fold improvement; the water solubility of example S47, example S95, example S97 has an improvement of 3 times or more, and examples S47, S72, S80, S95 and S97S are easier to make into a lyophilized powder or an aqueous solution dosage form, which solves the adverse effects of poor water solubility of platinum drugs in clinical application.
[0056] In Vivo Tumor Inhibition Experiment of Example
[0057] The inhibitory effects of example S47 and example S70 of the present disclosure on animal transplanted tumor S180 were tested.
[0058] Kunming mice, ♀, 22±1 g, were purchased from Shanghai Slac Laboratory Animal Co., Ltd. Certificate number: SCXK (Shanghai) 2013-0010-02. Feeding environment: SPF level. Example S47, example S70 and carboplatin, a positive control drug, were prepared with 5% glucose to the required concentration. Mice were subcutaneously inoculated with S180 sarcoma cells, and the drug administration was started on the next day of inoculation. The administration dose and scheme are shown in Table 4. The mice were killed on the eighth day, and the tumor was weighed and the tumor inhibition rate was calculated.
Tumor inhibition rate=(tumor weight in the control group−tumor weight in the treatment group)/tumor weight in the control group×100
TABLE-US-00004 TABLE 4 Therapeutic effects of example S47, example S70 and carboplatin in S180 sarcoma of mice Tumor Number of mice Tumor inhibition Dose Route of Before After weight (g) rate Group mmol/kg administration administration administration X ± SD % Control NS Ip, dl, 4 10 10 1.92 ± 0.33 group S47-Low 80 Ip, dl, 4 6 6 0.87 ± 0.18 54.7 dose S47- 160 Ip, dl, 4 6 6 0.53 ± 0.21 72.4 Medium dose S47-High 240 Ip, dl, 4 6 6 0.26 ± 0.12 86.5 dose S70-Low 80 Ip, dl, 4 6 6 0.92 ± 0.20 52.3 dose S70- 160 Ip, dl, 4 6 6 0.56 ± 0.17 70.8 Medium dose S70-High 240 Ip, dl, 4 6 6 0.30 ± 0.14 84.6 dose Carboplatin 160 Ip, dl, 4 6 6 0.78 ± 0.28 60.4
[0059] *P<0.01 compared with the control group
[0060] Conclusion: Example S47 and example S70 have obvious inhibitory effects on the growth in S180 sarcoma of mice, and the inhibitory effects at equimolar concentrations are significantly better than carboplatin, an anticancer drug widely used in clinical practice, and example S47 and example S70 have a good dose-effect relationship, and have a good clinical application prospect.